Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Donepezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 8/20 | 0.98 |
| ▸ | BCHE | P06276 | 8/20 | 0.98 |
| ▸ | FAAH | O00519 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | PDE5A | O76074 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | APP | P05067 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | MAOB | P27338 | 1/20 | 0.98 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Donepezil SCHEMBL8265876 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL2149 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3851203 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL12043710 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3516 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL5060933 | 0.98 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1559622 | 0.98 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL4979379 | 0.98 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL356844 | 0.98 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1815 | 0.98 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773339-A4 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2009-07-29 | — | — | EP | claimed |
| US-20080234485-A1 | 1-Benzyl-4-[ (5,6-Dimethoxy-1-Indanon) -2-Yl] Methylpiperidine Hydrobromide or Crystals Thereof | EISAI R & D MANAGEMENT CO., LTD., (JP) | 2008-09-25 | — | — | US | claimed |
| US-20080114173-A1 | Crystalline Form of Donepezil Hydrochloride | DR. REDDY'S LABORATORIES, INC. | 2008-05-15 | — | — | US | claimed |
| EP-1773339-A2 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2007-04-18 | — | — | EP | claimed |
| WO-2007013922-A1 | 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON)-2-YL] METHYLPIPERIDINE HYDROBROMIDE OR CRYSTALS THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2007-02-01 | — | — | WO | claimed |
| WO-2006015338-A2 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-02-09 | — | — | WO | claimed |
| WO-2004099142-A1 | HYDROBROMIDE SALT OF BENZYL-PIPERIDYLMETHYL-INDANONE AND ITS POLYMORPHS | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-18 | — | — | WO | claimed |
| EP-3033077-A1 | TREATMENT OF COGNITIVE IMPAIRMENT WITH COMBINATION THERAPY | Universiteit Maastricht (NL) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022417-A1 | TREATMENT OF COGNITIVE IMPAIRMENT WITH COMBINATION THERAPY | TAKEDA GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
| US-20150051246-A1 | Treatment of Cognitive Impairment with Combination Therapy | UNIVERSITEIT MAASTRICHT (NL) | 2015-02-19 | — | — | US | disclosed |
| EP-1773339-A4 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2009-07-29 | — | — | EP | disclosed |
| EP-1773339-A4 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2009-07-29 | — | — | EP | disclosed |
| US-20090171094-A1 | 1-BENZYL-4-[(5, 6-DIMETHOXY- 1- INDANON)- 2- YL]-METHYL PIPERIDINE P-TOLUENESULFONATE OR CRYSTAL THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| WO-2007013922-A1 | 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON)-2-YL] METHYLPIPERIDINE HYDROBROMIDE OR CRYSTALS THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006090263-A1 | STABLE FORM I DONEPEZIL HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006015338-A3 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006030249-A1 | DONEPEZIL SALTS SUITABLE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006015338-A2 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006015338-A2 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-02-09 | — | — | WO | disclosed |
| WO-2004099142-A1 | HYDROBROMIDE SALT OF BENZYL-PIPERIDYLMETHYL-INDANONE AND ITS POLYMORPHS | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051246-A1 | Treatment of Cognitive Impairment with Combination Therapy | ACHE, PDE12, BCHE | ACHE 1/4885BCHE 3/4885FAAH 832/4885 |
| US-20080114173-A1 | Crystalline Form of Donepezil Hydrochloride | PSEN1, H1-5, BCHE | ACHE 4/4885BCHE 3/4885FAAH 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.